DIA 2021 Virtual Global Annual Meeting

Component Type: Forum
Level: Advanced
CE: ACPE 1.00 Knowledge UAN: 0286-0000-21-548-L04-P; CME 1.00; IACET 1.00; RN 1.00

As drug development moves toward precision and targeted medicines, megatrials which include tens of thousands of participants are uncommon. But the developers of COVID-19 vaccines launched complex trials of this size in 2020, encountering not just the challenges of massive clinical trials but also those of running clinical trials during the pandemic. In this forum, senior-level executives from biopharma companies which conducted COVID-19 vaccine trials will discuss the experience of clinical operations in this context, sharing what they expected and did not expect, lessons learned, and what they will take forward to the conduct of future research.

Learning Objectives

Describe some of the unique challenges of launching extremely large clinical trials; Discuss unique and innovative practices and solutions that clinical teams developed to manage these challenges; Assess ideas for best practices that can be applied to future clinical trial conduct.

Chair

Lindsay McNair, MD, MPH, MS

Speaker

Panelist
Melanie Ivarsson, PhD, MBA

Panelist
Dawn M Furey

Panelist
Sarah Tweedy